Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 160

1.

Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma.

Tarazona N, Smyth EC, Peckit C, Chau I, Watkins D, Rao S, Starling N, Cunningham D.

Ther Adv Med Oncol. 2016 Mar;8(2):104-12. doi: 10.1177/1758834015621669.

2.

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study.

Moorcraft SY, Fontana E, Cunningham D, Peckitt C, Waddell T, Smyth EC, Allum W, Thompson J, Rao S, Watkins D, Starling N, Chau I.

BMC Cancer. 2016 Feb 17;16(1):112. doi: 10.1186/s12885-016-2145-0.

3.

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer erbitux, radiotherapy and UFT (PERU) trial.

Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I.

Oncotarget. 2016 Feb 5. doi: 10.18632/oncotarget.7208. [Epub ahead of print]

4.

Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?

Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I.

Clin Colorectal Cancer. 2015 Nov 27. pii: S1533-0028(15)00148-6. doi: 10.1016/j.clcc.2015.11.003. [Epub ahead of print]

PMID:
26747392
5.

Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey.

Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, Watkins D, Rao S.

Trials. 2016 Jan 9;17:17. doi: 10.1186/s13063-015-1105-3.

6.

Validity and Reliability of a Measurement of Objective Functional Impairment in Lumbar Degenerative Disc Disease: The Timed Up and Go (TUG) Test.

Gautschi OP, Smoll NR, Corniola MV, Joswig H, Chau I, Hildebrandt G, Schaller K, Stienen MN.

Neurosurgery. 2015 Dec 21. [Epub ahead of print]

PMID:
26702840
7.

Management of resectable colorectal lung metastases.

Moorcraft SY, Ladas G, Bowcock A, Chau I.

Clin Exp Metastasis. 2016 Mar;33(3):285-96. doi: 10.1007/s10585-015-9774-6. Epub 2015 Dec 10.

PMID:
26659389
8.

Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.

Young K, Chau I.

Drugs. 2016 Jan;76(1):13-26. doi: 10.1007/s40265-015-0510-y.

PMID:
26620367
9.

The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.

Barton S, Peckitt C, Sclafani F, Cunningham D, Chau I.

Eur J Cancer. 2015 Dec;51(18):2732-9. doi: 10.1016/j.ejca.2015.08.030. Epub 2015 Nov 19. Review.

PMID:
26608121
10.

Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.

Kasenda B, Kühnl A, Chau I.

Expert Rev Hematol. 2016 Feb;9(2):123-35. doi: 10.1586/17474086.2016.1122513. Epub 2016 Jan 6.

PMID:
26581237
11.

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma.

Young K, Smyth E, Chau I.

Therap Adv Gastroenterol. 2015 Nov;8(6):373-83. doi: 10.1177/1756283X15592586. Review.

12.

Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.

Fontana E, Smyth EC, Cunningham D, Rao S, Watkins D, Allum WH, Thompson J, Waddell T, Peckitt C, Chau I, Starling N.

Gastric Cancer. 2015 Nov 5. [Epub ahead of print]

PMID:
26541768
13.

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.

Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M; Bacchus investigators.

BMC Cancer. 2015 Oct 23;15:764. doi: 10.1186/s12885-015-1764-1.

14.

PD-1 and PD-L1 blockade in gastrointestinal malignancies.

Lote H, Cafferkey C, Chau I.

Cancer Treat Rev. 2015 Dec;41(10):893-903. doi: 10.1016/j.ctrv.2015.09.004. Epub 2015 Sep 21. Review.

PMID:
26412280
15.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J.

N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.

16.

The timed up and go test for lumbar degenerative disc disease.

Gautschi OP, Corniola MV, Joswig H, Smoll NR, Chau I, Jucker D, Stienen MN.

J Clin Neurosci. 2015 Dec;22(12):1943-8. doi: 10.1016/j.jocn.2015.04.018. Epub 2015 Aug 7.

PMID:
26260113
17.

Does surgery have a role in managing incurable gastric cancer?

Thrumurthy SG, Chaudry MA, Chau I, Allum W.

Nat Rev Clin Oncol. 2015 Nov;12(11):676-82. doi: 10.1038/nrclinonc.2015.132. Epub 2015 Aug 11. Review.

PMID:
26260039
18.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.

PMID:
26162609
19.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.

Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.

PMID:
26095784
20.

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.

Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius B, Keränen SR, Bateman A, Hickish T, Tabernero J, Thomas J, Brown G, Oates J, Chau I.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):303-12. doi: 10.1016/j.ijrobp.2015.03.038. Epub 2015 Apr 4.

PMID:
26031368
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk